| Dr Marie Claude Jean, | |
|
707 E Main St, Middletown, NY 10940-2650 | |
| (845) 333-7373 | |
| (845) 333-7342 |
| Full Name | Dr Marie Claude Jean |
|---|---|
| Gender | Female |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 707 E Main St, Middletown, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124791496 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2021019783 (Missouri) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marie Claude Jean, 707 E Main St, Middletown, NY 10940-2650 Ph: (845) 333-7373 | Dr Marie Claude Jean, 707 E Main St, Middletown, NY 10940-2650 Ph: (845) 333-7373 |
News Archive
Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models.
Schering-Plough Corporation (NYSE: SGP) today announced the introduction of CLARITIN 12-Hour, the only 12-hour allergy medicine found in the allergy aisle. New CLARITIN 12-Hour lasts all day and provides effective, non-drowsy relief from the worst indoor and outdoor allergy symptoms. The product is available for adults and children ages six and up.
The team of researchers found that although in 2006 a second dose was added to the vaccination roster, the decrease in deaths occurred largely during the time when just one shot was recommended. While chickenpox-related deaths are now relatively rare, the new two-dose regimen may eliminate them altogether, they said. The double dose will further reduce sick days and medical care associated with chickenpox and its complications, the study authors said.
Postprocedural asymmetry following percutaneous coronary intervention is associated with an increased risk of adverse clinical outcome, particularly in patients with suboptimal expansion, researchers report.
A team of researchers led by Mayo Clinic and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified specific potential therapeutic targets for the most aggressive and lethal form of pancreatic cancer.
› Verified 3 days ago